Ufuk Ilgen
Ufuk is a rheumatologist. Currently, he is doing his MSc in Translational Medical Research Programme at Heidelberg University, Germany. His main clinical and research interests are the immunopathological background of autoimmune diseases, hereditary fever syndromes and amyloidoses, and endothelial cell biology. He is a member of the Turkish Society for Rheumatology and the European Lupus Society. He is a member of the EMEUNET Country Liaisons Sub-Committee.
| Oral OP0066 | Wednesday 11.06.2025 4.40pm Co-morbidities in Rheumatoid Arthritis – Cancer and cardiovascular events Author: R Westermann (Denmark) Title: The risk of cancer recurrence with bDMARD treatment in patients with rheumatoid arthritis and a history of cancer: a nationwide Danish register-based cohort study  In this nationwide observational cohort study of Danish rheumatoid arthritis patients with a solid cancer in remission (2002 to 2021), treatment with bDMARDs (TNF inhibitors, IL-6 inhibitors, rituximab and abatacept) was not found to be associated with increased risks of cancer recurrence compared with csDMARD treatment. |
| Oral OP0069 | Wednesday 11.06.2025 5.10pm Co-morbidities in Rheumatoid Arthritis – Cancer and cardiovascular events Author: A Beltagy (Egypt) Title: GLP1 agonists mitigate the risk of cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors In this propensity score-matched, retrospective, registry-based real-world cohort study, GLP1 agonist use was found to confer protection from acute coronary syndromes and deep vein thromboses in rheumatoid arthritis patients receiving treatment with JAK inhibitors. |
| Poster POS0031 | Wednesday 11.06.2025 3.54pm Clinical Poster Tours – Difficult to Treat Rheumatoid Arthritis Author: B Kuriya (Canada) Title: Exploring the Potential for Cardiorenal-Metabolic Therapies to Target Comorbidities in Early Rheumatoid Arthritis In this real-world study from the Canadian Early Arthritis Cohort, 54% of early rheumatoid arthritis patients had at least one baseline cardiorenal-metabolic (CRM) condition and 45% met approved indications (type 2 diabetes, obesity, heart failure or overweight plus weight-related complications) for CRM therapy, primarily for obesity and diabetes. |
| Oral OP0323 | Friday 13.06.25 10.30am Rheumatoid Arthritis – Prevention and Early Treatment Author: TD Maarseveen (Netherlands) Title: Hand-dominant joint involvement pattern associates with favorable, and polyarthritis with unfavorable, treatment response to both csDMARDs and bDAMRDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trials When classified by joint involvement patterns before treatment, early rheumatoid arthritis patients in the NORD-STAR and BeSt trials with hand-dominant disease improved more compared to those with foot-dominant, polyarticular and oligoarticular disease, even after correction for baseline disease activity (CDAI). Female sex, but not RF/ACPA positivity, were associated with worse disease activity during follow-up. |
| Oral OP0330 | Friday 13.06.2025 11.40am Rheumatoid Arthritis – Prevention and Early Treatment Author: M Doumen (Belgium) Title: One-in-three patients with early rheumatoid arthritis experience persistent disease impact despite control of inflammation: a longitudinal trajectory analysis of two randomized controlled trials In the pooled post-hoc longitudinal trajectory analysis of the Care in early RA (CareRA) and CareRA2020 trials, one-in-three patients with early rheumatoid arthritis experienced persistent disease impact and disability, despite intensive treatment to target and improvement of inflammatory activity. |